Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

One-Year Follow-up on Liraglutide Treatment for Prediabetes and Overweight/Obesity in Clozapine- or Olanzapine-Treated Patients

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. The association between depressive mood and ischemic heart disease: a twin study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A multisystem composite biomarker as a preliminary diagnostic test in bipolar disorder

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. New drug candidates for depression - a nationwide population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Mortality in unipolar depression preceding and following chronic somatic diseases

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review

    Research output: Contribution to journalReviewResearchpeer-review

  2. An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Treatment with most antipsychotics is associated with an increased risk of weight gain and metabolic disturbances. In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. The aim of this study was to investigate whether the beneficial effects of the 16-week intervention were sustained beyond the intervention period.

METHOD: One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide and lipids comparing one-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels.

RESULTS: From end of treatment to the one-year follow-up, body weight had increased in the liraglutide-treated group. However, compared to baseline levels, the placebo-subtracted body weight loss remained significantly reduced (-3.8 kg, 95% CI: -7.3 to -0.2, P = 0.04). Fasting glucose, glycated hemoglobin, C-peptide and lipids had each returned to baseline levels one year after stopping liraglutide.

CONCLUSION: The body weight reduction during 16 weeks of liraglutide treatment was partially sustained one year after the intervention was completed. However, the improvements in other metabolic parameters returned to baseline levels. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalActa Psychiatrica Scandinavica
Volume139
Issue number1
Pages (from-to)26-36
Number of pages11
ISSN0001-690X
DOIs
Publication statusPublished - Jan 2019

Bibliographical note

© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

    Research areas

  • clozapine, GLP-1, liraglutide, olanzapine, overweight, prediabetes, schizophrenia

ID: 55633064